GB201119910D0 - Self-assembling peptides - Google Patents

Self-assembling peptides

Info

Publication number
GB201119910D0
GB201119910D0 GBGB1119910.6A GB201119910A GB201119910D0 GB 201119910 D0 GB201119910 D0 GB 201119910D0 GB 201119910 A GB201119910 A GB 201119910A GB 201119910 D0 GB201119910 D0 GB 201119910D0
Authority
GB
United Kingdom
Prior art keywords
peptides
self
amino acids
active compounds
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1119910.6A
Other versions
GB2496654A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Reckitt and Colman Overseas Ltd
Original Assignee
University of Manchester
Reckitt and Colman Overseas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester, Reckitt and Colman Overseas Ltd filed Critical University of Manchester
Priority to GB1119910.6A priority Critical patent/GB2496654A/en
Publication of GB201119910D0 publication Critical patent/GB201119910D0/en
Priority to PCT/GB2012/052830 priority patent/WO2013072686A2/en
Publication of GB2496654A publication Critical patent/GB2496654A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

Peptide-based hydrogels in which the peptides coalesce such that they 'self-assemble' to form a hydrogel. Such hydrogels can be used to deliver pharmaceutically active compounds through mucosal tissue. The peptides have 2-20 amino acids. Preferred peptides have 6-10 amino acids (e.g. FEFEFKFK, FEFEFRFR). The peptides have been found to adhere well to mucosal tissue allowing for good delivery of pharmaceutically active compounds and may be used to treat pain, inflammation and infection of the oral cavity (e.g. sore throat).
GB1119910.6A 2011-11-18 2011-11-18 Self-assembling peptides Withdrawn GB2496654A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1119910.6A GB2496654A (en) 2011-11-18 2011-11-18 Self-assembling peptides
PCT/GB2012/052830 WO2013072686A2 (en) 2011-11-18 2012-11-15 Self-assembling peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1119910.6A GB2496654A (en) 2011-11-18 2011-11-18 Self-assembling peptides

Publications (2)

Publication Number Publication Date
GB201119910D0 true GB201119910D0 (en) 2012-01-04
GB2496654A GB2496654A (en) 2013-05-22

Family

ID=45475354

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1119910.6A Withdrawn GB2496654A (en) 2011-11-18 2011-11-18 Self-assembling peptides

Country Status (2)

Country Link
GB (1) GB2496654A (en)
WO (1) WO2013072686A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009358A1 (en) 2015-07-13 2017-01-19 Universiteit Gent Hydrogel-forming peptides
US20200246472A1 (en) * 2016-02-16 2020-08-06 Vrije Universiteit Brussel Hydrogel-forming composition for controlled release
CN111647044B (en) * 2020-06-05 2022-02-08 东北农业大学 Antibacterial peptide rich in phenylalanine as well as preparation method and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
WO1999004764A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
US7449180B2 (en) * 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
AU2003302237A1 (en) * 2002-12-06 2004-06-30 Adaptive Therapeutics, Inc. Novel cyclic peptides comprising alpha-, beta- and gamma- amino acids
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US7846891B2 (en) * 2003-10-17 2010-12-07 Massachusetts Institute Of Technology Self-assembling peptides for regeneration and repair of neural tissue
EP1843776A4 (en) * 2004-07-06 2011-05-11 3D Matrix Inc Purified amphilic peptide compositions and uses thereof
WO2006116524A1 (en) * 2005-04-25 2006-11-02 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US20070148246A1 (en) * 2005-08-11 2007-06-28 Dan Luo Nucleic Acid-Based Matrixes
WO2008039483A2 (en) * 2006-09-26 2008-04-03 Massachusetts Institute Of Technology Modified self-assembling peptides
US20100221341A1 (en) * 2009-02-27 2010-09-02 Drexel University Alanine-Based Peptide Hydrogels
US20110117195A1 (en) * 2009-11-18 2011-05-19 National Cheng Kung University Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
WO2011116072A1 (en) * 2010-03-16 2011-09-22 Escape Therapeutics, Inc. Hybrid hydrogel scaffold compositions and methods of use

Also Published As

Publication number Publication date
WO2013072686A3 (en) 2013-08-15
GB2496654A (en) 2013-05-22
WO2013072686A2 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
MX2009002314A (en) Pharmaceutical compositions comprising hgh for oral delivery.
TW201129368A (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
NZ608502A (en) Polypeptides that bind to human complement component c5
EP2933264A3 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2012140704A (en) METHOD FOR PREVENTION AND / OR TREATMENT OF FIBROSIS AND / OR REMOVAL OF THE CORNETAL (OPTIONS), METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR PREVENTION AND / OR TREATMENT OF FIBROSIS AND / OR REMOVAL PRACTICE
MX337830B (en) Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions.
JP2016516023A5 (en)
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
MX357801B (en) Gadd45beta targeting agents.
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ603200A (en) Peptides and their use
NZ700296A (en) Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
ES2397889A1 (en) Pgc-1alpha-modulating peptides
EA200702522A1 (en) SYSTEM OF DELIVERY OF MEDICINES IN THE CAVITY OF THE MOUTH AND METHODS OF ITS APPLICATION
MX2012014521A (en) Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation.
EA200802350A2 (en) DRUG DELIVERY SYSTEM
MX2019012014A (en) Therapeutic medicine for fibrous disease.
MY190257A (en) Optimised subcutaneous therapeutic agents
MX353649B (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery.
GB201119910D0 (en) Self-assembling peptides
WO2011064316A3 (en) Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)